Literature DB >> 24673562

Effect of serum interleukin 21 on the development of coronary artery disease.

Ru Ding1, Wenwu Gao, Zhiqing He, Mingfang Liao, Feng Wu, Sili Zou, Lan Ma, Chun Liang, Zonggui Wu.   

Abstract

There has been more and more evidence to confirm the essential role of inflammatory processes in the development of coronary artery disease (CAD). Interleukin-21 (IL-21), the most recently discovered CD132-dependent cytokine, plays a key role in regulating inflammation. The aim of the study was to understand the effect of peripheral IL-21 on the pathogenesis and progression of CAD. Serum level of IL-21 in 92 CAD patients and 73 controls was measured by the enzyme-linked immunosorbent assay. Data showed that IL-21 expression was significantly increased in CAD than in controls (p < 0.001). Interestingly, when comparing IL-21 level with different genders, male subjects revealed higher IL-21 than female subjects (p = 0.024). Also, we observed that patients with hypertension had upregulated level of serum IL-21 (p = 0.002). Moreover, serum level of IL-21 was positively correlated with total cholesterol level (p = 0.015) or low-density lipoprotein cholesterol (p = 0.0009) of CAD cases. In addition, we analyzed IL-21 level with the severity of CAD, and identified that cases with 3-vessel affected had significantly elevated level of IL-21 than those with 1-vessel or 2-vessel affected. These data suggested that serum level of IL-21 may be closely associated with the development and progression of CAD.
© 2014 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Interleukin 21; coronary artery disease; serum

Mesh:

Substances:

Year:  2014        PMID: 24673562     DOI: 10.1111/apm.12246

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

1.  IL-21 promotes myocardial ischaemia/reperfusion injury through the modulation of neutrophil infiltration.

Authors:  Kejing Wang; Shuang Wen; Jiao Jiao; Tingting Tang; Xin Zhao; Min Zhang; Bingjie Lv; Yuzhi Lu; Xingdi Zhou; Jingyong Li; Shaofang Nie; Yuhua Liao; Qing Wang; Xin Tu; Ziad Mallat; Ni Xia; Xiang Cheng
Journal:  Br J Pharmacol       Date:  2017-04-12       Impact factor: 8.739

2.  Interleukin-21 polymorphism affects gene expression and is associated with risk of ischemic stroke.

Authors:  Guanggang Li; Ruxiang Xu; Yinghua Cao; Xiaodong Xie; Zhendong Zheng
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

3.  Critical role of Interleukin 21 and T follicular helper cells in hypertension and vascular dysfunction.

Authors:  Bethany L Dale; Arvind K Pandey; Yuhan Chen; Charles D Smart; Fanny Laroumanie; Mingfang Ao; Liang Xiao; Anna E Dikalova; Sergey I Dikalov; Fernando Elijovich; Jason D Foss; Natalia R Barbaro; Justin P Van Beusecum; Serpil M Deger; Aseel Alsouqi; Hana A Itani; Allison E Norlander; Matthew R Alexander; Shilin Zhao; T Alp Ikizler; Holly M Scott Algood; Meena S Madhur
Journal:  JCI Insight       Date:  2019-04-23

4.  Correlation of pre-operative circulating inflammatory cytokines with restenosis and rapid angiographic stenotic progression risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents.

Authors:  Jinling Sun; Hui Yu; Haining Liu; Dongyu Pu; Junhui Gao; Xiaodong Jin; Xiqiang Liu; Aiguo Yan
Journal:  J Clin Lab Anal       Date:  2019-11-14       Impact factor: 2.352

Review 5.  Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic?

Authors:  Meena S Madhur; Fernando Elijovich; Matthew R Alexander; Ashley Pitzer; Jeanne Ishimwe; Justin P Van Beusecum; David M Patrick; Charles D Smart; Thomas R Kleyman; Justin Kingery; Robert N Peck; Cheryl L Laffer; Annet Kirabo
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

Review 6.  The Effect of Periodontitis on Expression of Interleukin-21: A Systematic Review.

Authors:  Archana Mootha; Sankari Malaiappan; N D Jayakumar; Sheeja S Varghese; Julie Toby Thomas
Journal:  Int J Inflam       Date:  2016-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.